New horizons for promising influences of sulforaphane in the management of metabolic syndrome: a mechanistic review.

IF 3.1 4区 医学 Q2 PHARMACOLOGY & PHARMACY Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2024-12-19 DOI:10.1007/s00210-024-03706-3
Mohammad Masoumvand, Elmira Ramezani, Yaser Eshaghi Milasi, Vafa Baradaran Rahimi, Vahid Reza Askari
{"title":"New horizons for promising influences of sulforaphane in the management of metabolic syndrome: a mechanistic review.","authors":"Mohammad Masoumvand, Elmira Ramezani, Yaser Eshaghi Milasi, Vafa Baradaran Rahimi, Vahid Reza Askari","doi":"10.1007/s00210-024-03706-3","DOIUrl":null,"url":null,"abstract":"<p><p>The disorder known as metabolic syndrome (MetS) represents a substantial threat to society since it is linked to a higher risk of heart disease, diabetes, stroke, and other health issues. Although there is no known cure for metabolic syndrome, lifestyle changes in diet and physical activity can help. Sulforaphane (SFN), a compound in cruciferous vegetables, has been recognized as a promising treatment for addressing metabolic syndrome. The information was compiled after a thorough search of four databases, PubMed, Scopus, Web of Sciences, and Google Scholar. This analysis includes 86 studies that include clinical and nonclinical SFN investigations in diseases connected to metabolic syndrome. Research has shown that sulforaphane is a prospective treatment option for obesity, type 2 diabetes mellitus (T2-DM), and associated metabolic disorders due to its capacity to regulate fatty acid production and glucose management. Many molecular processes have been investigated, including activating nuclear factor erythroid 2-related factor 2(Nrf2), activating nuclear factor erythroid 2(NF-E2), reducing reactive oxygen species, and upregulating insulin receptor substrate 1(IRS-1) and other suggested mechanisms. The current review established many facts in favor of SFN's prospective benefits in metabolic syndrome. More studies in this field involving human studies are necessary to determine whether SFN may effectively treat metabolic syndrome.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-024-03706-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The disorder known as metabolic syndrome (MetS) represents a substantial threat to society since it is linked to a higher risk of heart disease, diabetes, stroke, and other health issues. Although there is no known cure for metabolic syndrome, lifestyle changes in diet and physical activity can help. Sulforaphane (SFN), a compound in cruciferous vegetables, has been recognized as a promising treatment for addressing metabolic syndrome. The information was compiled after a thorough search of four databases, PubMed, Scopus, Web of Sciences, and Google Scholar. This analysis includes 86 studies that include clinical and nonclinical SFN investigations in diseases connected to metabolic syndrome. Research has shown that sulforaphane is a prospective treatment option for obesity, type 2 diabetes mellitus (T2-DM), and associated metabolic disorders due to its capacity to regulate fatty acid production and glucose management. Many molecular processes have been investigated, including activating nuclear factor erythroid 2-related factor 2(Nrf2), activating nuclear factor erythroid 2(NF-E2), reducing reactive oxygen species, and upregulating insulin receptor substrate 1(IRS-1) and other suggested mechanisms. The current review established many facts in favor of SFN's prospective benefits in metabolic syndrome. More studies in this field involving human studies are necessary to determine whether SFN may effectively treat metabolic syndrome.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
萝卜硫素在代谢综合征治疗中的新前景:机制综述。
这种被称为代谢综合征(MetS)的疾病对社会构成了重大威胁,因为它与心脏病、糖尿病、中风和其他健康问题的高风险有关。虽然没有已知的治疗代谢综合征的方法,但改变饮食和体育活动的生活方式会有所帮助。萝卜硫素(SFN)是十字花科蔬菜中的一种化合物,被认为是治疗代谢综合征的一种有希望的治疗方法。这些信息是在对PubMed、Scopus、Web of Sciences和b谷歌Scholar四个数据库进行彻底搜索后编制的。该分析包括86项研究,包括与代谢综合征相关疾病的临床和非临床SFN调查。研究表明,萝卜硫素具有调节脂肪酸生成和葡萄糖管理的能力,是肥胖症、2型糖尿病(T2-DM)和相关代谢紊乱的前瞻性治疗选择。许多分子过程已被研究,包括激活核因子2相关因子2(Nrf2),激活核因子2(NF-E2),减少活性氧,上调胰岛素受体底物1(IRS-1)和其他可能的机制。目前的综述建立了许多事实,支持SFN在代谢综合征中的潜在益处。要确定SFN是否能有效治疗代谢综合征,还需要更多涉及人体的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.20
自引率
5.60%
发文量
142
审稿时长
4-8 weeks
期刊介绍: Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.
期刊最新文献
Quantitative structure-activity relationship (QSAR) hazard assessment of the banned pesticides by the National Agency for Food and Drugs Administration and Control. RNA-Seq transcriptomic landscape profiling of spontaneously hypertensive rats in youth treated with a ARNI versus ARB. "Methyl jasmonate: bridging plant defense mechanisms and human therapeutics". A complete sojourn on nanotechnological advancements and nanocarrier applications in psoriasis management. Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1